Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
TBC filgotinib Arthritis, Rheumatoid Withdrawn
TBC daprodustat Anemia due to chronic kidney disease Withdrawn
TBC abaloparatide Osteoporosis, postmenopausal women Withdrawn
TBC tirzepatide Diabetes mellitus, type 2 Cancelled
TBC ferumoxytol Iron deficiency anemia Withdrawn
TBC Darunavir / cobicistat HIV infection Withdrawn
TBC omaveloxolone Friedreich’s ataxia Active
TBC crovalimab paroxysmal nocturnal hemoglobinuria (PNH) Active
TBC teprotumumab Thyroid Eye Disease (TED), acute Active
TBC teprotumumab Thyroid Eye Disease (TED), chronic Active